Press & News
Latest from Celluminova
11/112024
Celluminova Secures Funding to Drive Development of Brain Tumor Treatment
Swedish life science company Celluminova has successfully raised SEK 8.1 million in seed funding for the continued development of its patented drug candidate, p- HTMI,...
Read more
17/62024
Celluminova receives Orphan Drug Designation in the EU for p-HTMI in malignant glioma
Celluminova, a privately owned Life Science company specialized in identification of cancer stem cells, announces that the European Commission has granted Orphan Drug Designation for...
Celluminovas läkemedelskandidat p-HTMI beviljas särläkemedelsstatus i EU för maligna gliom
Celluminova, ett privatägt Life Science företag som specialiserar sig på identifiering av cancerstamceller, meddelar att Europeiska Kommissionen beviljat p-HTMI särläkemedelsstatus. Celluminovas patenterade substans p-HTMI är den första molekylen...
13/42022
Listen to an interview with Celluminova’s CEO
The business incubator LEAD talked to Celluminova’s CEO in their interview series “Startup talks”. Link to interview
11/42022
Read an interview with Celluminova’s CEO
The business incubator LEAD released an article about us. Read to learn about the history of Celluminova. Link to article
3/52021
Listen to an episode of the podcast Speed Of Life about Celluminova
Celluminova’s CEO participated in the Speed Of Life podcast series. Listen to learn about where the name Celluminova comes from and why our product GlioStem...
